Background. Urinary biomarkers are used in assessment of severe, clinical oxidative stress. Little is known, however, about their diagnostic value within the normative range.
Introduction
Normal metabolism generates potentially harmful entities, such as reactive oxygen species (ROS), among others [1] . Excessive production of these ROS may exceed the body's antioxidant defense system and lead to oxidative stress [2] that damages cell lipids, proteins, and DNA [3] . Systemic and cellular oxidative stress can also result from dietary influences, external radiation, and environmental chemicals [4] [5] [6] .
Free radicals attacking DNA in the nucleus of cells can lead to point mutations that may also produce singleand double-strand DNA breaks and deletions. Urinary excretion of 8-hydroxy-2-deoxyguanosine (8-OHdG) is an indicator of in vivo DNA oxidation [7] , signifying the occurrence of strand breaks and potential mutagenesis. Free radical attacks on lipids in cell and organelle membranes represent lipid peroxidation. Urinary excretion of thiobarbituric acid reactive substances (TBARS) is an indicator of in vivo membrane oxidation [8] .
Exogenous substances in the diet may modulate and modify the oxidation process down to the cellular level [9, 10] . Iron participates in most of these oxidative reactions [11] . On the one hand, it has been asserted that higher oral ingestion of dietary iron, increased body iron stores, or both augment the burden of in vivo oxidative stress [12, 13] . On the other hand, a number of dietary components have antioxidant properties that blunt or quench the free-radical action of oxidants, producing balancing or protective effects within the cellular oxidation milieu [14] . Carotenoids have been linked with free-radical quenching properties potentially of health benefit since 1981 [15] . Carotenoids are found in the diet in green, yellow, and orange plants [16] , and edible derivatives of the palm fruit, genus Elaeis, are among the most carotenoid-rich options for the human diet [17] .
In a metabolic study conducted on apparently normal, healthy Guatemalan men who received periodic challenges with oral iron supplements along with variable doses of an oral supplement mixture derived from a distillate of red palm oil, we address the main hypothesis of mitigation of systemic oxidation by concurrent high intake of dietary antioxidants. We also present findings that relate to variation in urinary 8-OHdG and TBARS excretion; this is forged within the widespread question in analytical chemistry and clinical medicine as to whether fluctuations of biomarkers from the upper to the lower borders of the normative distribution, but within the normal range, has a physiological significance.
Subjects and methods
This was a longitudinal metabolic study with repeated measures and no separate control group; each subject served as his own control. Seventeen healthy adult men were recruited at the local national university in Guatemala City to participate in one of the two phases that composed the study: 5 in the first phase (pilot study) and 12 in the second phase (definitive intervention trial). These subjects and procedures are part of a study on fecal oxidation published previously [18] .
The study and analysis proceeded in stages. The objectives of the pilot phase were to determine the effect of a selected dose of oral iron on urinary biomarkers of oxidation and to assess the effects on the biomarkers of systemic oxidation of the added refined palm oil, which is needed to dilute the antioxidant concentrate. We continued in the definitive intervention phase to test the efficacy and dose-response effect of the palm fruit-derived antioxidants to reduce any oxidative effects of the iron challenge. Based on some unexpected outcomes and interesting observations through these two phases, we here provide some post hoc analysis and interpretation of some of the observations from the study.
For the purpose of subject recruitment, a short prescreening questionnaire about health status and smoking habits was given to the potential subjects after the objectives and procedures of the study had been explained to them. Smokers, persons with a history of gastrointestinal disorders, intolerance to iron supplements, or hematologic disorders, and those who were taking other nutritional supplements, including iron supplements, were not eligible for inclusion in the study. Anyone who presented with or developed an inflammatory or infectious condition during the study was excluded from the analysis. Eligible subjects who signed the informed consent form were asked to give a blood sample for initial routine hematologic screening for anemia, and those who were not anemic were invited to continue in the study. No candidates were excluded on the basis of hematologic or inflammatory status at baseline. During the study, they were requested not to engage in intense physical activity in order to avoid the internal generation of free radicals.
Ethical approval of the study protocol was granted by the Bannatyne Campus Research Ethics Board at the University of Manitoba, Canada, and the Human Subjects Committee of the Center for Studies of Sensory Impairment, Aging and Metabolism (CeSSIAM) in Guatemala City. The subjects signed written informed consent forms after the purpose, nature, inconveniences, risks, benefits, and compensation had been explained to them.
Oral supplementation regimens and sample collection
Two supplemental iron treatments were used within the first phase (pilot study). The first consisted of 120 mg of elemental iron in the form of FeSO 4 (Fer-In-Sol, Mead Johnson Nutricionales, Bristol-Myers Squibb, Quito, Ecuador, 125 mg of iron/mL). The second consisted of 120 mg of iron from FeSO 4 plus 5 mL of commercial refined palm oil (Olmeca, Fraijanes, Guatemala). After 3 days of baseline urinary collection, both iron treatments were administered in two cycles of supplementation of 7 days each, separated by a 14-day washout period. The last supplementation period was followed by a final 12-day washout period. The second phase (intervention trial) used two concentrations of the antioxidant source, Carotino® Tocotrienol Carotene Mixed Concentrate (CTCMC, Carotino®, Johor Darul Takzim, Malaysia), added to the oral iron in a sampling frame similar to that of the first phase. Five milliliters of commercial refined palm oil was mixed with 0.4 and 0.8 g of CTCMC and compared with the same iron-in-oil treatment used in the pilot phase. In this phase, the subjects received both dosages of CTCMC, presented in a randomized sequence.
In both phases, the participants ingested the supplements in the fasting state and were allowed to drink an ad libitum draught of water to help them swallow the iron-containing mixtures. Approximately 60 minutes after ingesting the supplement doses, they were given a breakfast meal.
Morning urine samples were self-collected at home by the subjects, stored in 50-mL plastic urine collectors (Amsino International, Pomona, California, USA), and transported to the study site in iceboxes with Blue Ice gel. The samples were separated into 1-mL aliquots and frozen at -50°C (Forma Scientific, International, Marietta, Ohio, USA) until analysis for quantification of urinary 8-OHdG, TBARS, and creatinine. Each subject provided three urine samples during baseline, two during each washout period on nonconsecutive days, and seven during active supplementation. In total, 110 urine samples were collected during the pilot study and 360 during the definitive intervention trial.
Assay procedures
Quantification of the oxidative DNA adduct in urine, 8-hydroxy-2'-deoxyguanosine 8-OHdG), was done with the commercial competitive in vitro enzyme-linked immunosorbent assay Bioxytech 8-OHdG-EIA Kit Quantitative Assay for 8-hydroxy-2'-deoxyguanosine (Cat. No. 21026, OXIS Health Products, Portland, Oregon, USA). Plates were read with an ELx800 absorbance microplate reader (Biotek, with microplate data collection and analysis software Gen5, Biotek, Biotek Instruments, Winooski,Vermont, USA). Urinary thiobarbituric acid reactive substances (TBARS), measured as a malondialdehyde (MDA)-thiobarbituric acid adduct and expressed as MDA equivalents, were determined with the commercial OXItek TBARS Assay Kit ZMC (Cat. No. 0801192, Zeptometrix Corporation, Buffalo, NY, USA), using a UV-Vis Spectronic 21D spectrophotometer (Spectronic Instruments, Bausch & Lomb, Rochester, NY, USA). Both 8-OHdG and TBARS values were normalized with urinary creatinine, determined in the clinical laboratory of the Sanatorio Nuestra Señora del Pilar, a private hospital in Guatemala City.
Dietary intake diaries
Because dietary iron, fiber, and antioxidants such as vitamin C, vitamin E, and carotenoids could be confounders of the responses seen in the study, we assessed the daily intakes of these nutrients with the use of a food diary. Details of the method are provided in a previous publication [18] ; we summarize the pertinent features here. We asked the participants to record their food consumption during two separate 7-day periods (including weekends). In both phases, the subjects recorded their total intake of food and beverages, including drinking water, using common household measures. We collected 224 days out of a maximum of 238 days (14 days per participant × 17 participants) of dietary data. The reported food portions were converted from household measures to grams. The total iron, fiber, carotenoids, vitamin E, and vitamin C contents of each food were estimated using the USDA online food composition database [19] , the Food Composition Table for the Central American area [20] , and nutritional labels on food products.
Data handling and statistical analysis
We first addressed the main hypothesis of whether antioxidant supplements quench iron-induced oxidation. When oral iron supplementation induced no significant increments in urinary TBARS and 8-OHdG excretion, we concluded that the main question could not be addressed with the present design. We then undertook three levels of post hoc analysis. The first was a comparison of the observed range of urinary oxidation biomarkers with values for healthy volunteer subjects. The next was an examination of the withinindividual associations between the two biomarkers in both static (correlation association) and kinetic (kappascore association) contexts. The final was to explore evidence for a suppression of urinary biomarker excretion with consumption of CTCMC.
The variables are presented as descriptive statistics using the arithmetic mean, standard deviation (population distribution), or standard error of the mean (metabolic sequence). A variety of formats, including scattergrams, bar graphs, and time-sequences plots, have been used to illustrate the findings. The values for the oxidative biomarkers TBARS and 8-OHdG have been routinely normalized to the urinary creatinine concentration in the same sample.
The paired t-test was used to compare biomarker responses under contrasting conditions within the same experimental subject. Because of the asymmetric nature of the main-effect hypothesis, a onetailed approach was applied to test the hypothesis of an increased urinary biomarker response with oral iron supplementation. Pearson's product-moment least-squared regression was used to test numerical associations between the normalized biomarker concentrations. Association in the kinetic time-sequence format was assessed by Cohen's kappa score, using the following grading system for quality of agreement: < 0.20 (poor), 0.20 to 0.40 (fair), 0.40 to 0.60 (moderate), 0.60 to 0.80 (good), and 0.80 to 1.00 (excellent) [21] . The kappa analysis examines how each biomarker tracks the other for up or down changes in urinary concentration, as illustrated in the Appendix. Differences in average urinary biomarkers between antioxidantexposed and antioxidant-nonexposed periods were compared by the paired t-test with a one-tailed assumption. A p value less than .05 was considered to indicate statistical significance.
Results and discussion
Demographic and hematologic characteristics of the subjects Table 1 provides data on age, weight, body composition, and hemoglobin concentration for the subjects of each of the two phases of the study and for the combined sample. All subjects were young adult men, apparently healthy, with normal hemoglobin concentrations at the beginning of the study. After the subjects had received a total of 1,680 and 2,520 mg of supplemental iron during the pilot study and the intervention trial, respectively, there were no significant changes in hemoglobin concentrations (p = .15 and p = .29, respectively; data not shown).
Dietary intakes of iron and antioxidant compounds
The dietary analysis did not reveal any excesses in the intakes of antioxidants or iron (dietary oxidant) that might have influenced the antioxidant status of the participants. The mean daily fiber intake, 19.2 ± 10.9 g/day, was half the recommended intake of 38 g per day [22] . The mean vitamin C intake for all the participants was 74.6 ± 78.8 mg/day, which is twice the Estimated Average Requirement (EAR) of 37 mg/day specified by the Food and Nutrition Board, Institute of Medicine (IOM) standards [23] . The participants consumed an average of 6.8 ± 5.1 mg/ day of vitamin E, slightly below the IOM EAR of 8 mg/day [23] . There is no official intake recommendation for carotene as an antioxidant [23] . The total individual daily intakes of carotenoids were well below the level that would satisfy vitamin A requirements [23, 24] . In terms of potential oxidants, the mean daily intake of dietary iron, expressed as both heme and nonheme iron, was 15.9 ± 7.3 mg, which is 74% of the World Health Organization/Food and Agriculture Organization EAR [25] for men, assuming the lowest dietary bioavailability for iron (5%) [24] .
Effect of oral iron supplementation on urinary biomarker excretion
The aspect of the pilot study that compared the urinary biomarker responses to iron, with and without unrefined palm oil, showed no suppression of the response by the addition of oil (data not shown). Therefore, no distortion of the response by the lipid emulsion format of the definitive trial was expected. The main effect hypothesis of our experimental design related to suppression of the iron-induced increment in urinary excretion of TBARS and 8-OHdG by concomitant administration of CTCMC. Testing this hypothesis presupposes the existence of such an ironrelated response to be suppressed. Figure 1A and 1B shows composite bar graphs with the mean creatininecorrected TBARS concentrations for various treatments across both phases of the study. Figure 1A compares the concentrations for all collections that were not associated with iron supplementation, with those for the remaining collections during oral iron administration in the pilot phase. The iron was administered with and without oil emulsion. There was no evidence for a significant increase in biomarker excretion with iron (p = .09 by one-tailed ANOVA). In figure 1B , we perform a comparable analysis for the urinary TBARS in the intervention phase of the study, comparing no iron administration with the combined treatment with iron and oil; there is a similar lack of statistical significance according to one-tailed ANOVA (p = .46). Figure 1C illustrates the comparison between no iron supplementation and the situation after intake of iron and oil together for the pilot phase related to 8-OHdG. These findings confirm the pattern for TBARS; the one-tailed ANOVA has a p value of .09. When treatments were dichotomized for supplementary iron exposure alone and no iron treatment in the intervention phase (panel D), no significant increment in 8-OHdG was seen (p = .24). Thus, with the absence of response of the biomarker to iron supplementation, the hypothesis that CTCMC might modify such iron-related oxidative changes becomes moot. In fact, in neither phase of the study could we confirm the findings of Schümann et al. [26] in three healthy German university students of a urinary biomarker increase to 120 mg of oral iron. On a logical basis, our failure to confirm the German findings in the pilot study might have pushed aside any justification for testing for any additional impact of oral antioxidants; however, on the possibility that the iron impact might be seen with a larger sample size of 12, we proceeded with the CTCMC treatments as originally planned.
One important consideration is that inquiry with these urinary biomarkers is typically directed toward situations of potent oxidant exposure or severe stress [27] [28] [29] [30] , and our challenge with 120 mg of oral iron may not reach the threshold for perturbation of the marker.
In the first phase of the study, we sought to examine a hypothesis regarding the efficacy of oral antioxidants, specifically a palm fruit extract (CTCMC), to mitigate systemic oxidation induced by 120 mg of daily oral iron in a dose-dependent manner. We selected TBARS and 8-OHdG as urinary biomarkers because they had been indicated to be responsive to this iron dose in an earlier trial of our group [26] . When we failed to reproduce the previous German experience [26] of a detectable and consistent response of the urinary biomarkers in both phases of our protocol, the question of mitigation of systemic, iron-induced oxidation by oral antioxidants became moot. The main effect question remains unresolved awaiting a modification of population setting, biomarker selection, or both for its definitive resolution.
Distribution of urinary oxidation biomarkers
Given that iron supplementation had no effect on biomarker concentrations in urine, post hoc analysis commenced with a focus on the distribution of values for urinary TBARS and 8-OHdG and their comparison with reference ranges for healthy adults identified as "controls" in several published reports [29, [31] [32] [33] [34] . As shown in figure 2 , the average TBARS concentration of the complete dataset from the pilot and intervention phases was 4.1 ± 2.0 nmol MDA/mL (n = 466 samples). When these results were compared with reference ranges from healthy subjects in three published reports [27, 28, 31] , it was noted that the three normative ranges from these studies do not agree well among one other. Our experimental values fall outside the two more restrictive ranges [28, 31] but coincide well with the 3 SD variance around the distribution of the third report [27] (fig. 2) . We found only one comparative report [29] in which the TBARS were normalized to creatinine, allowing for strict comparison with the way we expressed our findings. Their 6-SD span ranged from 0.03 nmol malondialdehyde (MDA)/mg of creatinine to 1.59 nmol MDA/mg of creatinine. For our distribution as normalized for creatinine, 29.6% were within the published reference range, whereas 70.4% fell outside and above.
A similar analysis was performed with the 466 specimens of urine analyzed for 8-OHdG concentration in both phases of the study (data not shown). They were compared with 8-OHdG reference ranges in healthy subjects in five published reports [32] [33] [34] [35] [36] , all of which were normalized for creatinine concentrations. The average 8-OHdG concentration was 41.1 ± 40.3 ng/mg creatinine. The comparative values of creatinine-normalized 8-OHdG in healthy control groups have a remarkably tight distribution, with the widest 3-SD span ranging from 2.3 to 31.7 ng/mg creatinine [34] . The 466 collections included values above literature consensus, which were far outside the 3-SD reference range for all these five publications [32] [33] [34] [35] [36] ; on examination, the latter is improbably narrow. However, we do not consider these to be "pathological. "
Mutual numerical and temporal associations of urinary TBARS and 8-OHdG
Our data provided several indications for the existence of a mutual association of the two urinary biomarkers. The Spearman correlation coefficient was r = 0.697 (p < .000001, n = 466). To examine the interbiomarker correspondence in a more kinetic sense, we did a Cohen kappa score analysis [21] of the correspondence of the direction of concentration change across consecutive collections over the various phases. The left-hand panel of the Appendix illustration provides an example of the temporal correspondence in one of the subjects with simple iron supplementation. Kappa score values from "fair" to "very good" were seen in 12 of the 17 studies, taking into consideration all treatments of the study. We noted that oral CTCMC flattened out the observed responses in the definitive intervention trial phase, as shown in the middle and left-hand panels of the Appendix. When kappa scores for the 12 studies from the definitive phase were recalculated, eliminating the antioxidant supplement treatments, the strength improved or remained the same in nine subjects and declined in the remaining three. Overall, we interpret this to be suggestive of a correspondent time-dependent kinetic pattern across the two urinary markers of systemic oxidation.
It is not difficult to ascribe a biologic meaning to large responses in biomarker concentrations when values rise well above reference limits in response to an induced stimulation or acquired disease. Of interest in this analysis is the correspondence of fluctuation of two biomarkers within the range considered not to be pathological as discussed above. Moreover, the two metabolites of interest originate from oxidation at two different cellular locations: lipid membranes for TBARS [8] and nuclear DNA for 8-OHdG [9] . The mutual associations of these two variables in regression analysis and the temporal kinetic fluctuations in the kappa score analyses suggest that observed variations within the normative range may reflect biologic effects and not merely random drift or analytical variation. Taiwanese researchers found a Spearman correlation of r = 0.71 between unadjusted urinary TBARS and 5-hydroxymethyluracil (5-HMU) [37] , another biomarker of DNA-oxidation. A parallel change in metabolites that represent oxidation at the membrane and the nucleus, i.e., at distinct intracellular sites, suggests the possibility that the oscillation reflects true biologic cellular processes in healthy individuals.
Oral antioxidant suppression of urinary biomarkers
Based on the evidence in figure 1 of no impact of iron, urinary excretion of the biomarkers with iron supplementation alone is comparable to the background state. With this caveat in mind, we compared concentrations of the urinary oxidation markers across the three treatment [27] , those in the light gray rectangle to control subjects from Actis-Goretta et al [28] , those in the black rectangle to control subjects in the study by Margonis et al [31] periods for TBARS and 8-OHdG ( fig. 4) . In figure 4A , on the left, we can see that there was significant reduction in creatinine-adjusted TBARS concentrations with oral supplementation with 0.4 g or 0.8 g of CTCMC with respect to the comparative situations (p = .03). Figure 4B , on the right, shows the evidence for a comparable suppression in creatinine-adjusted 8-OHdG with a significance of p = .02 with the respective dosages of the antioxidant supplement compared with situations without carotenes and tocotrienols.
In consequence, the potential implications of the consistent suppression observed after co-supplementation of iron with palm oil concentrates ( fig. 3) become even more intriguing. Discounting any influence of the iron, carotenes, tocotrienols, or both in the CTCMC reduce the excretion of both urinary TBARS and 8-OHdG as compared with the adapted state in which our subjects entered the metabolic study. A plausible interpretation of this effect is an antioxidant-mediated reduction in systemic oxidation. In a randomized intervention trial involving healthy adult subjects, 63 consecutive days of ingesting 111 mg of α-tocopherol equivalents and 1.24 mg of carotenoids produced a significant difference in plasma concentrations of malondialdehyde (MDA), an analogous biomarker to urinary TBARS, as compared with a control group [38] . Urinary 8-OHdG has also marked responses to interventions with oral antioxidant supplementation. In a randomized trial in Malaysia [37] , 6 months of daily supplementation with 160 mg of a 74% tocotrienol and 26% tocopherol mixture significantly reduced urinary 8-OHdG concentrations in healthy subjects over 50 years of age.
Limitations and strengths
We recognize a number of limitations in this study. The sample sizes of both phases were small, which may have been associated with an insufficient power to detect the expected iron-induced response in urinary biomarker excretion. Militating against this explanation, however, was the facile demonstration of a significant reduction in concentrations with the application of the antioxidant supplementation in the group of a dozen subjects in the definitive trial phase. Thus, the failure to replicate the iron-induced increments in systemic oxidation observed in the German setting in an earlier study [26] is probably not due to insufficient sample size. It is clear consequence, however, was an inability to provide any test of the main hypothesis regarding oral antioxidants mitigating iron-related oxidation. A strength of the study was the emergence of unexpected insights related to normative values for the two urinary oxidative biomarkers and the apparent responsiveness of the biomarkers within the normative range to concomitant signals across analytes and to a significant depression by an ingestion of large amounts of an oral antioxidant combination. 
Conclusions
We found no evidence in Guatemalan men of consistent induction of oxidation by oral iron reflected in the two oxidative biomarkers that have been promising indicators in a previous iron-challenge study [26] ; this prevented us from being able to test the central hypothesis of the study. Oral supplementation with a palm fruit extract, however, did produce consistent suppression of systemic oxidation below previously adapted levels, independently of any iron effect. The mutual association of day-to-day variation in biomarkers from distinct cellular components adds credibility to this suppression of urinary output representing a true antioxidant-related mitigation, but extensive further follow-up of the unexpected and interesting findings of this study will be required. BSL1  BSL2  BSL3  FEoil1  FEoil2  FEoil3  FEoil4  FEoil5  FEoil6  FEoil7  WO1  WO2  CTCB1  CTCB2  CTCB3  CTCB4  CTCB5  CTCB6  CTCB7  WO3  WO4  CTCA1  CTCA2  CTCA3  CTCA4  CTCA5  CTCA6  CTCA7  WO5  WO6   TBARS  8OHdG Creatinine-normalized TBARS (nmol MDA/mg creatinine) Creatinine-normalized 8-OHdG (ng/mg creatinine)
